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Abstract  
The peripheral benzodiazepine receptor (PBR) is a 18 kDa molecule mainly involved in cholesterol transport 
through the mitochondrial membrane. In microglia, PBR is expressed from the earliest stages of activation   and   
appears   to   exert   a   pro-inflammatory function. This molecule is commonly up-regulated in inflammatory, 
degenerative, infective and ischaemic lesions of the central nervous system but it has never been reported in 
glioma-infiltrating microglia. We examined two anaplastic astrocytomas showing minimal contrast-enhancement 
and therefore little damage of the blood brain barrier to minimise the presence of blood borne macrophages 
within tumour tissue. The two lesions were studied in vivo using positron emission tomography (PET) with the 
specific PBR ligand [11C](R)-PK11195 and the corresponding tumour tissue was investigated with an anti-PBR 
antibody. Glioma-infiltrating microglia were characterised for molecules involved in antigen presentation and 
cytotoxic activity. As comparison, PBR was investigated in three brains with multiple sclerosis (MS) and three 
with Parkinson's disease (PD). The expression profile of four anaplastic astrocytomas was also exploited and 
results were compared to the profile of eleven samples of normal temporal lobe and nine cases of PD. PET 
studies showed that [11C](R)-PK11195 binding was markedly lower in tumours than in the contralateral grey 
matter. Pathological investigation revealed that glioma-infiltrating microglia failed to express PBR and cytotoxic 
molecules although some cells still expressed antigen presenting molecules. PBR and cytotoxic molecules were 
highly represented in MS and PD. Evaluation of microarray datasets confirmed these differences. Our results 
demonstrated PBR suppression in glioma-infiltrating microglia and suggested that PBR may have a relevant role 
in modulating the anti-tumour inflammatory response in astrocytic tumours. 




Microglia are the resident immune cells of the central nervous system (CNS) [1]. They are ubiquitously 
distributed across brain regions in a "resting" state and constitute a network of surveillance and defence cells, 
with their cytoplasmic processes continuously scanning the surrounding microenvironment [2]. Upon detection 
of any insult to brain tissue, microglial cells undergo a process of activation that entails changes in their shape 
and function. Cytoplasmic processes shorten and thicken until cells appear to be indistinguishable from blood-
borne macrophages, begin producing a myriad of cell-signalling molecules and receptors, and acquire the 
capacity of antigen presentation, phagocytosis, migration and proliferation [3, 4]. Activation can be triggered by 
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a broad variety of stimuli including hypoxia, accumulation of insoluble molecules, infective agents or the contact 
with neoplastic cells [4]. In anaplastic astrocytomas and glioblastomas, microglia contribute significantly to the 
total tumour mass but the fact that neoplastic cells manage to survive and grow in their presence indicate the 
failure of normal defence mechanisms [5, 6]. The causes of poor microglial response to tumour cells are still 
unclear although recent studies have demonstrated glioma-infiltrating microglial cells show an impairment of 
antigen presenting functions [6-10]. 
The peripheral benzodiazepine receptor (PBR) is one of the earliest and most commonly expressed molecules 
during microglial activation in inflammatory, degenerative, vascular and infective CNS diseases [3, 5, 11]. For 
this reason, high levels of PBR are generally considered a marker of microglial activation [5], and the PBR-
specific ligand [11C](R)-PK11195 is widely used in positron emission tomography (PET) studies to trace 
microglial infiltrate as an in vivo indicator of tissue damage [11]. Also known as PK-11195 binding protein or 
translocator protein, the PBR is an 18 kDa molecule consisting of a five helices spanning the membrane lipid 
bilayer of the outer mitochondrial membrane and forming a heterotrimer together with a voltage dependent anion 
channel and an adenine nucleotide transporter [12, 13]. The PBR is expressed in several normal tissues with the 
highest levels in gonads and cortical cells of adrenal gland [14, 15] and its major function is to actively transport 
cholesterol and proteins through the mitochondrial membrane [13]. The actual role of PBR in microglial cells is 
still to be elucidated although recent studies in vitro [16] and animal model [17] suggested that it may exert a 
pro-inflammatory function. Interestingly, several studies have found high-PBR levels in tumour cells of 
glioblastomas and to a lesser extent of anaplastic astrocytomas [18] but none of them have mentioned glioma-
infiltrating microglial cells as possible source of PBR. 
Here, we present the results obtained during a feasibility study designed to explore the expression of PBR in 
human astrocytic tumours and the diagnostic use of [11C](R)-PK11195 PET-scan in neuro-oncology. We 
investigated PBR in vivo using [11C](R)-PK11195 PET imaging and with immunohistochemistry in tumour 
tissue. Tumour-infiltrating microglial cells were also characterised for the expression of molecules involved in 
antigen presentation and cytotoxic activity and results obtained in astrocytomas were compared with cases of 




This 27-year-old male presented with a 2-month history of seizures. MR-scan (1.5 Tesla Sonata scanner, 
Siemens, Erlangen, Germany) demonstrated a lesion of the right temporal lobe, which appeared 
inhomogeneously hypointense on T1-weighted sequences and hyperintense in the T2-weigh ted sequences. Only 
minimal enhancement was observed after administration of gadolinium (Fig. la). No therapy has been given prior 
to surgery but 800 mg/day of valproate. 
Case 2 
This 53-year-old female presented with a 4-year history of progressive dysesthesia in right upper and lower 
extremities. MRI-scan revealed a right fronto-insular intra-axial lesion that was inhomogeneously hypointense in 
T1-weighted images and hyperintense in the T2-weighted sequences (Fig. 1c). Only mild diffuse enhancement 
was seen. No radiotherapy, chemotherapy or corticosteroid therapy were administered prior to the PET scanning 
and surgical resection. 
Both patients underwent surgical debulking and samples were submitted for pathological examination. This 
study was approved by the Ethics Committee of the Kyoto University Graduate School of Medicine (No. 420) 
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Fig. 1 Gadolinium-enhanced MRI (a, c) and [11C](R)-PK11195 PET superimposed on 3D MRI (b, d). The 
intensity of the lesions is low in the T1-weighted images with minimal contrast enhancement (a, patient 1,  left 
frontal region; c, patient 2,  left frontotemporal region; arrowheads). Both lesions show decreased [11C](R)-
PK11195 binding than the normal grey matter (b, d; BP binding potential) 
 
 
Materials and methods 
PET imaging acquisition and analysis 
Both patients underwent [11C](R)-PK11195 PET scan (Advance, General Electric, Milwaukee, WI, USA) and a 
three-dimensional T1-weighted MRI (magnetisation prepared rapid acquisition gradient-echo sequence; TR/TE, 
2000/4.38; 3 Tesla Trio scanner, Siemens) prior to surgery. PET study was performed in three-dimensional 
acquisition mode as previously reported [19]. A 6 mCi bolus of [11C](R)-PK11195 was injected intravenously 
into the patients 30 sec after the acquisition scan started. Dynamic PET data were acquired over 60 min as 18 
temporal frames. Attenuation correction factors were determined using a 15-min eight-emission scan. Data were 
reconstructed with a ramp filter. Kinetic modelling was performed by Logan graphical analysis without blood 
sampling [20]. We used the time-activity course of the radioactivity in a reference tissue (normal grey matter 
contralateral to the tumour) of each patient as the input function. The binding potential (BP) was calculated as 
BP = DVR - 1, where DVR is the ratio of the volume of distribution (DV) in the region of interest to that in the 
reference region. The DVR was calculated as the slope of the Logan plot that was obtained by linear regression 
analysis. Finally, PET images were coregistered onto 3D MRI images by using the mutual information algorithm 
implemented in SPM2 (Wellcome Department of Imaging Neuroscience, UCL, London, UK). 
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Pathological investigation 
Surgical samples were fixed in 10% buffered formalin and paraffin embedded. Five-micron sections were cut 
and stained with haematoxylin-eosin (HE). Immunohistochemistry was performed using the avidin-biotin 
complex/ peroxidase (ABC) method with antibodies directed against PBR (monoclonal clone 8D7; dilution 
1:200; kindly supplied by Dr. Pierre Casellas, Department of Immunology-Oncology, Sanofi Synthelabo, 
Montpellier, France), MHC class II antigen (HLA-DR) (MHCII) (Dako Cytomaton, Glostrup, Denmark; clone 
CR3/43; dilution 1:200), CD80 (B7.1) (Abeam, Cambridge, UK, clone MAB104 dilution 1:100), CD86 (B7.2) 
(Sigma, Deisenhofen, Germany, clone B72-H2, dilution 1:100), Tumour Necrosis Factor alpha (TNF-alpha) 
(Chemicon, Termecula, CA, USA, clone 195, dilution 1:200), inducible nitric oxide synthase (iNOS) (R&D, 
Wiesbaden, Germany, clone 2B2-D2, dilution 1:50) and cyclooxigenase 2 (COX-2) (BD Transduction Lab, Palo 
Alto, CA, USA, clone 33, dilution 1:250). For all antibodies, the sections were pretreated in 1 mM EDTA (pH 8) 
for 20 min in microwave oven at 500 W. 
The epitope recognised by the anti-PBR antibody corresponding to the cholesterol binding domain (amino acids 
158-169) [12, 21] was compared with all the known human proteins (Blast/Fasta; www.pir.georgetown.edu) and 
no match was found other than with the three PBR isoforms. The protocol for PBR was assessed using normal 
adrenal gland that constitutively contains high level of the protein [15]. We also tested the anti-PBR antibody 
with Western-blot analysis with extracts from adrenal gland and normal frontal cortex. A standard protocol was 
followed [22]. 
The extent of expression of microglial PBR in non-neoplastic CNS diseases was examined in active 
demyelination from three post-mortem brains with MS, and in the substantia nigra of three brains with PD. 
Brains with MS were donated to the UK MS Tissue Bank and PD cases were donated to the UK PD Society 
Tissue Bank, both at Imperial College, London. These samples were previously immunostained for MHCII 
antigen and they were known to contain activated microglial cells. Lymphocytes, neutrophils, endothelial cells 
and smooth muscle cells present within tumour tissues were considered internal positive controls, as they are 
known to constitutively express PBR [13, 23]. 
Evaluation of microarray datasets 
The differences between microglial in astrocytomas and non-neoplastic CNS diseases were also explored by 
examining the expression profile of four anaplastic astrocytomas, which are part of a group of gliomas we have 
studied with expression microarrays (Affymetrix, Santa Clara, CA, USA, U-133 Plus 2; available online GEO 
database, GEO submission GSE2817) [for details see reference 24]. Tumours were compared with eleven normal 
temporal lobes removed in course of surgery for intractable epilepsy. Anaplastic astrocytomas and normal 
temporal lobes were characterised for the extent of microglial infiltrate using MHCII antigen and for the 
expression of PBR and COX-2 (immunohistochemical stains are described above). As example of a non-
neoplastic CNS condition, we explored a dataset obtained from the substantia nigra of nine PD cases 
(Affymetrix, U-133 A) [25]. Cases of PD were compared with the expression profile of the substantia nigra of 
seven age-matched normal brains. The three PD cases used for immunohistochemistry were part of the group 
used for expression microarrays. We investigated the expression of molecules involved in microglial response 
including MHC class II antigen (HLA-DR), CD40, CD80 (B7.1), CD86 (B7.2), CD40, Toll-like receptors (TLR) 
1-8 and 10, and TNF-alpha receptors 1. Astrocytomas and PD cases were compared to the respective control 
tissue. Details on microarray data processing and normalisation are reported in the respective references [24, 25]. 
Statistical analysis was performed using a Mann-Whitney test. Analysis of expression profiles did not include 
other molecules contributing to microglial immune response such as TNF-alpha, iNOS and COX-2 because 
probes for these molecules are not contained in the Affymetrix arrays. 
Results 
PET findings 
[11C](R)-PK1195 PET studies revealed that the binding of the ligand was markedly lower in both tumours than 
in the contralateral grey matter [Figs, 1b, 1d] [Fig. 2]. The tumour/normal grey matter ratios of the integrated 
radioactivity and BP in each patient were 0.67 (patient 1) and 0.51 (patient 2), and 0.68 (patient 1) and 0.51 
(patient 2), respectively. 
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Fig. 2 Regional time activity curves (TAC) extracted from the dynamic [11C](R)-PK11195 PET data of both 




Validation of the anti-PBR monoclonal antibody 
Normal adrenal gland demonstrated expression of PBR in the cells of the zona glomerulosa, reticularis and 
fasiculata and the sections of normal brain showed expression in a few perivascular macrophages. Western-blot 
analysis revealed a band of 18 kDa in both extracts corresponding to the known molecular weight of the PBR. 
Signal seen in brain tissue was much weaker than signal in adrenal gland. 
Pathological findings 
Both tumours were diagnosed as anaplastic astrocytoma (grade III, WHO classification) [26] by two independent 
neuropathologists. They were composed of astrocytic cells with fibrillary cytoplasm and moderate to severe 
nuclear pleomorphism. Mitotic activity was brisk in both cases. No necrosis and, vascular and endothelial 
proliferation was seen (Fig. 3a). As seen with the immunoreaction for MHCII, both tumours contained a 
substantial number of activated microglial cells and macrophages that accounted for -40% of the total number of 
cells (Fig. 3b). The anti-PBR antibody demonstrated expression in a few tumour cells and no expression in 
microglia (Fig. 3c) PBR-positive lymphocytes were observed within the vessels and leptomeninges (Fig. 3d). 
Leptomeningeal arteries showed PBR expression in endothelium and smooth muscle cells of the tunica media 
whereas normal vessels entrapped with tumours vessels showed weak expression. In both cases, some microglial 
cells expressed CD80 and CD86. TNF-alpha was present in a few microglial cells mainly located in the subpial 
tissue whereas iNOS and COX-2 were only observed in a few neoplastic cells. 
The three cases of MS showed intense PBR expression in activated microglial cells surrounding active plaques 
as well as in microglia and macrophages within areas of demyelination (Fig. 4a). Strong expression of PBR was 
also seen in activated microglia in the substantia nigra of the three PD cases (Fig. 4b). In all the samples 
examined we observed PBR expression in the wall of several medium sized and small arteries. Both MS and PD 
cases featured expression of CD86, TNF-alpha, iNOS and COX-2 in microglial cells. 
Evaluation of microarray datasets 
Immunohistochemical stains for MHCII revealed a diffuse microglial infiltrate in the four anaplastic 
astrocytomas used for microarrays analysis compared to normal control tissue. The PBR was expressed in 
tumour cells and in a few microglial cells. Notably, all the tumours showed a considerably high number of 
MHCII-positive microglial cells than PBR-positive and COX-2 positive microglia. Expression analysis of 
anaplastic astrocytomas showed levels of PBR as low as control brains. Expression of MHCII, CD86 and TLRs 
4 and 5 in anaplastic astroctyomas were significantly higher than normal brains (P < 0.1) whereas CD80 and 
CD40 were high but expression values did not reach significance. TNF-alpha receptor 1 was only mildly 
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elevated and TLRs 1-3, 6-8 and 10 were as low as normal brain. In the substantia nigra of PD cases, the 
expression of PBR, TLRs 4 and 5 and TNF-alpha 1 receptor were increased compared to normal nigra (P < 0.1); 
MHCII, CD40, CD80 and CD86 showed borderline levels compared to controls. All values of expressions were 
normalised to the respective control tissue (Fig. 5). 
 
Fig. 3 The tumour in patient 1 shows the features of an anaplastic fibrillary astrocytoma (a; HE staining; × 10). 
The immunoreaction for the MHC class II antigen demonstrates a considerable number of activated microglia 
(b, × 10). PBR is expressed in a few tumour cells but it is undetectable in microglia (c; patient 1 × 25). PBR 
expression is observed in the leptomeningeal lymphocytes and leptomeningeal vessels (d, patient 1, × 4) 
 
 
Published in : Journal of neuro-oncology (2007), vol. 85, pp. 95-103 
Status : Postprint (Author’s version) 
 
Fig. 4 Intense expression of PBR is seen in activated microglia in an active MS plaque (a) and Parkinson's 
disease (b, nigra) (ABC/ peroxidase) 
 
 
Fig. 5 This diagram demonstrates the expression of mRNA of PBR, MHCII, CD86, TLR4 and 5 and TNF alpha 




We observed that activated microglial cells infiltrating two cases of anaplastic astrocytoma do not express PBR. 
This finding is interesting because it differs from all imaging studies with [11C](R)-PK11195 [11], microarray 
studies [5], studies in vitro [27, 28], animal model [3, 29, 30] and post-mortem brains [22] that showed high 
expression of PBR in activated microglia in a variety of inflammatory, degenerative, infective and vascular CNS 
disorders. Our approach of combining the evaluation of PBR using [11C](R)-PK11195 PET-scan and 
immunohistochemistry offered the advantage of studying the binding capacity of this molecule in vivo and, on 
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tissues its distribution in the cell types constituting the two astrocytomas without the changes that may occur 
examining microglia in vitro, outside the complexity of interactions with other cell types [5]. In addition, these 
two cases represented a rare opportunity and an excellent model to investigate microglial PBR because they 
showed low-PBR expression in neoplastic cells and minimal contrast enhancement indicating minimal disruption 
of the blood brain barrier and therefore little presence of blood-borne macrophages within tumour tissue. 
We first excluded that the lack of PBR in glioma-infiltrating microglia depended on the techniques used. Time 
activity curves showed good perfusion of the radioligand indicating that low BP seen in PET studies did not 
depend on reduced blood flow within tumours. The dose of unlabelled PK11195 injected for PET imaging along 
with the labelled ligand was too low to saturate binding sites. Positive immunohistochemical reactions obtained 
with adrenal gland, MS and PD confirmed that the anti-PBR antibody 8D7 is suitable for routinely processed 
tissue and the search in protein Blast/Fasta, and Western-blot analysis confirmed its specificity. Finally, PBR 
immunolabelling in tumour cells and intravascular and leptomeningeal mononuclear inflammatory cells that 
normally produce PBR [13, 23] indicated good preservation of the antigen in tumour samples. Taken altogether, 
these findings confirmed that the very low-PET signal and the lack of immunolabelling in tumour tissue were 
consistent with a very low expression of PBR in tumour tissue. 
In the present two cases only a minority of neoplastic cells expressed PBR. The presence of a limited number of 
PBR-positive tumour cells was essential to our study because it allowed us for a better evaluation of its 
expression in microglial cells. Previous studies that investigated PBR in human astrocytomas using 
autoradiography with [3H] PK11195 [31-38] or immunohistochemistry [18, 39-41] observed that the great 
majority of glioblastomas have high-PBR expression whereas anaplastic astrocytomas show variable expression 
with some lesions showing PBR levels as high as low-grade examples and normal brain [39]. The function of 
PBR in tumour cells is still unclear but some authors suggested that this molecule may have a role in inducing 
proliferation and regulating apoptosis [41]. Interestingly, none of these studies reported intra-tumoural microglial 
cells and macrophages to be a source of PBR. Using autoradiography, Benavides et al. [32] examined PBR 
expression in glioblastomas, MS, brain infarct and normal brains. They observed a considerable increase in PBR 
expression in all lesions and a spatial correlation between increased expression of PBR and accumulation of 
macrophages in MS plaques and infarcts but not in glioblastomas where PBR expression was reportedly limited 
to tumour cells. 
Our results obtained with the two cases studied with PET-scan combined with the results of expression 
microarrays showed that glioma-infiltrating microglia in anaplastic astrocytomas express very low levels or no 
PBR and that glioma-infiltrating microglia have impaired cytotoxic activity (lack of TNF-alpha, COX-2 and 
iNOS) although they retain antigen presenting functions, at least in some cells (expression of CD86 and TLRs 4 
and 5). In addition, we demonstrated that microglial response in anaplastic astrocytomas substantially differs 
from the response in non-neoplastic conditions such as MS and PD. These findings elicit an intriguing 
hypothesis on the role of PBR in microglial immune functions. The PBR is one of the most common molecules 
expressed by microglial cells during activation but its role in these cells is unknown and the molecular pathway 
linking the functions of PBR to microglial response has not been elucidated [5]. In a mouse model, Banati et al. 
[42] showed that PBR is up-regulated at the early stages of activation when microglial cells still show a ramified 
morphology and suggested that PBR may be a key molecule in microglial immune response. Recent in vitro 
studies demonstrated that binding of PBR with the antagonist PK-11195 can suppress lipopolysaccaride-induced 
expression of TNF-alpha and COX-2 [16] and that PK-11195 may block store-operated channels mediated Ca2+ 
influx and the production of COX-2 induced by platelet-activating factor [43]. These results indicate that PBR 
may exert a pro-inflammatory activity and suggest a correlation between modulation of mitochondrial PBR and 
cellular inflammatory response with store-operated channels acting as the molecule that links the two pathways. 
In human glioblastomas, Hussain et al. [6] observed that glioma-infiltrating microglia and macrophages 
separated from tumour cells up-regulate MHCII and TLRs 1, 2, 3 and 4, show very low levels of CD86 and lack 
of CD80 and TNF-alpha, even after stimulation with lipopolysaccaride. Finally, previous studies in glial tumours 
did not document expression of COX-2 and iNOS in glioma-infiltrating microglia although they showed 
expression in tumour cells and their increase with tumour grade [44, 45]. If these and our results are considered 
altogether, we may speculate that down-regulation of PBR in anaplastic astrocytomas can interfere with the 
immune response of glioma-infiltrating microglia by suppressing cytotoxic activity. Interestingly, He et al. [46] 
documented very low expression of TNF-alpha and iNOS in activated microglia surrounding brain metastatic 
non-small cell lung carcinomas suggesting that mechanisms that lead to impairment of microglial anti-tumour 
activity may be common in primary and secondary CNS tumours. 
Positron emission tomography studies performed here showed that [11C] (R) PK11195 binding in both 
astrocytomas was markedly lower than in the contralateral grey matter. Turkheimer et al. [47] recently reported 
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that normal brains show a baseline up-take of [11C] (R) PK11195 due to the presence of PBR in the tunica media 
and endothelium of intra-parenchymal arteries. In the current study, immunohistochemical stains demonstrated 
lack of microglial PBR in normal vessels entrapped within neoplastic tissue but still preserved expression in 
leptomeningeal vessels. Such reduction of the baseline expression of PBR in vessels justifies a binding of [11C] 
(R) PK11195 in astrocytomas lower than normal grey matter. In addition, absent expression of PBR in microglia, 
low expression in neoplastic cells and intra-tumoural vessels might suggest that molecules present in tumour 
microenvironment can down-regulate PBR. 
Two previous studies have investigated PBR expression in human gliomas by using [11C](R)-PK11195 PET [48, 
49]. Junck et al. [48] examined three low-grade and three anaplastic astrocytomas, three glioblastomas and one 
case defined as indeterminate grade. They observed detectable signal in eight lesions but only 60 and 80 min 
after injection and not in the early images. In addition, tumour/grey matter ratio, tumour/white matter ratio and 
tumour radioactivity did not correlate with tumour grade. Their findings are not comparable to ours because 
these authors did not use the R-enantiomer of PK11195, which exhibits maximum contrast at ~10 min after 
injection approaching the equilibrium thereafter. Moreover, many lesions investigated in their study showed 
contrast enhancement and therefore damage of the blood brain barrier. Disruption of the blood brain barrier 
allows blood-borne mononuclear cells to infiltrate tumour tissue and such a recruitment of haematogenous cells 
that highly express PBR may give confounding results. The results obtained by Pappata et al. [49] were in 
keeping with the known kinetic properties of [11C](R) PK-11195 but a parallel with our findings is also difficult 
because they studied a case of glioblastoma, hence a lesion with significant damage of the blood brain barrier. 
In conclusion, we have shown that activated microglial cells infiltrating anaplastic astrocytomas may not express 
PBR as they do in neuroinflammatory, neurodegenerative, vascular and infective CNS diseases. Our results 
suggest that PBR has an important in modulating the inflammatory microglial response against tumour cells and 
highlight the complexity of the in vivo response of microglia in astrocytic tumours. Absence of PBR in 
microglial cells and in the wall of intra-tumoural vessels suggests that tumour microenvironment may contain 
molecules capable of inducing down-regulation of PBR. Further studies are required to elucidate the role of PBR 
in microglial immune response and the causes leading to its suppression in high-grade astrocytomas. 
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